News Listing Page
- Early trial results indicate Yescarta CAR-T therapy improves survival for adults who relapse from large B-cell lymphoma
Aug 04, 2021 -- Yescarta is 60% more effective than the current standard of care in treating people with large B-cell lymphoma (LBCL) who did not respond well to, or relapsed after, the first line of treatment, according to early results of a global Phase 3 clinical trial.
- Study to assess post-vax COVID-19 antibodies in people with cancer
Jul 01, 2021 -- The goal of the study is to build on early knowledge of how the COVID-19 vaccine works in patients with cancer who, depending on the type of treatment they are undergoing, may have a suppressed or over-stimulated immune system.
Last modified: Jul 26, 2018